TAKE Solutions has implemented its first mobile patient reported outcomes tool ‘PaDiSys’ for a biopharma company focused on the development of small molecule drugs to treat male and female reproductive disorders. TAKE is the exclusive reseller worldwide of PaDiSys through a strategic partnership with NowPos, a company that specialises in developing mobile-based solutions for life sciences.
The PaDiSys solution reportedly helps sponsors to improve patients’ treatment adherence and compliance towards the protocol and patient reported outcomes. PaDiSys also allows sponsors to walk away from a paper based approach to filling out questionnaires and assessments during clinical trials, thereby enabling the clinical staff to closely monitor patient compliance and safety. Clinicians and site staff are equipped with easy-to-use analytical dashboards that monitor patient data in real time, and can intervene when necessary to ensure compliance. With quick deployment, implementation and simple use for both subjects and clinicians, there is a much higher adherence to a study regimen, thus improving trial compliance, claims the company.
Ram Yeleswarapu, President & CEO said, “TAKE has been providing solutions and services to life sciences customers for 12 years, and safety is one of our core areas of expertise. In partnership with NowPos, we can provide biopharma companies with cutting edge mobile technology and quality, while reducing costs and accelerating trial execution.”
Vikram Marla, CEO, NowPos M-Solutions said, “The PaDiSys platform caters to clinical research studies across therapeutic areas. Flexible configuration allows the product to be used in different types of research, ranging from drug efficacy, behavioural, observational, adherence, quality of life, or lifestyle based studies in various therapeutic areas. He further added, “PaDiSys was developed from the ground up by embracing key aspects of mobile technology and the need for a low cost turnkey solution. Our strategic partnership with TAKE, along with their vast network of clients, is helping us reach out to the core pharma community needing to improve their PRO and study compliance by many folds.”
EH News Bureau